List of Mytesi drug patents

Mytesi is owned by Napo Pharms Inc.

Mytesi contains Crofelemer.

Mytesi has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Mytesi are:

  • US7341744

Mytesi was authorised for market use on 31 December, 2012.

Mytesi is available in tablet, delayed release;oral dosage forms.

Mytesi can be used as symptomatic relief of non-infectious diarrhea.

The generics of Mytesi are possible to be released after 31 October, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7341744 NAPO PHARMS INC Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer
Jun, 2022

(8 months ago)

US9585868 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(8 years from now)

US8962680 NAPO PHARMS INC Methods and compositions for treating HIV-associated diarrhea
Oct, 2031

(8 years from now)

Drugs and Companies using CROFELEMER ingredient

Market Authorisation Date: 31 December, 2012

Treatment: Symptomatic relief of non-infectious diarrhea

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in